XNAS
ALMR
Market cap1.92bUSD
Sep 11, Last price
27.89USD
1D
0.43%
1Q
26.77%
IPO
26.77%
Name
Alamar Biosciences Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Key people
Yuling Luo
CEO, Chairman, Founder, Technologist · since 2023
Steve Chen
COO, Founder · since 2023
Xiao-Jun Ma
Chief Technology Officer · since 2021
Tao Fu
Senior Advisor
Tod White
Chief Business Officer, Chief Financial Officer · since 2023
Senior Advisor
Valuation
Title in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT |